NCT01765790

Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors

A Phase 1 Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-MIF Antibody in Subjects With Malignant Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 68 (actual)
• Sponsor: Baxalta now part of Shire · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-MIF antibody in subjects with malignant solid tumors (Arm 1) and in subjects with metastatic adenocarcinoma of the colon or rectum (Arm 2).

Conditions

• Metastatic Adenocarcinoma of the Colon or Rectum
• Malignant Solid Tumors

Interventions

Type	Name	Description
BIOLOGICAL	Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody	* Dosing every 2 weeks * Intravenous injection
BIOLOGICAL	Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody	* Dosing weekly * Intravenous injection

Timeline

• Start date: 2012-06-14
• Primary completion: 2016-07-28
• Completion: 2016-07-28
• First posted: 2013-01-10
• Last updated: 2021-05-05

Locations

5 sites across 2 countries: United States, Germany